Back to Search Start Over

A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy.

Authors :
Zeng Y
Mayne N
Yang CJ
Liu J
Cui F
Li J
Liang W
He J
Source :
Translational lung cancer research [Transl Lung Cancer Res] 2021 Apr; Vol. 10 (4), pp. 1690-1699.
Publication Year :
2021

Abstract

Background: Chemotherapy is a common treatment for patients with resected non-small cell lung cancer (NSCLC). However, there are few models for predicting the survival outcomes of these patients. Here, we developed a clinical nomogram for predicting overall survival (OS) in this cohort.<br />Methods: A total of 16,661 patients with resected NSCLC treated with chemotherapy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified prognostic factors and integrated them into a nomogram. The model was subjected to bootstrap internal validation using the SEER database and external validation using a database in China and the National Cancer Database (NCDB). The model's predictive accuracy and discriminative ability were tested by calibration and concordance index (C-index).<br />Results: Age, sex, number of dissected lymph nodes, extent of surgery, N stage, T stage, and grade were independent factors for OS and were integrated into the model. The calibration curves for probability of 1-, 3-, and 5-year OS showed excellent agreement between the predicted and actual survivals. The C-index of the nomogram was higher than that of the Tumor-Node-Metastasis staging system for predicting OS (training cohort, 0.62 vs. 0.58; China cohort, 0.68 vs. 0.63; NCDB cohort, 0.59 vs. 0.57).<br />Conclusions: We developed a nomogram that can present individual prediction of OS for patients with resected NSCLC who are undergoing chemotherapy. This practical prognostic tool may help clinicians in treatment planning.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-1220). WL serves as an unpaid associate editor-in-chief from Apr 2018 to Apr 2021. The other authors have no conflicts of interest to declare.<br /> (2021 Translational Lung Cancer Research. All rights reserved.)

Details

Language :
English
ISSN :
2218-6751
Volume :
10
Issue :
4
Database :
MEDLINE
Journal :
Translational lung cancer research
Publication Type :
Academic Journal
Accession number :
34012785
Full Text :
https://doi.org/10.21037/tlcr-20-1220